Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMAT - ultrafast tomography for coronary artery disease -- Ignore unavailable to you. Want to Upgrade?

To: John T. Hardee who wrote (3536)	7/14/2000 1:31:26 PM
From: TA2K	Read Replies (1) \| Respond to of 3725

Reasons To Expect Continuation Of Uptrend In IMAT Stock: * Imatron is fast approaching the greatest selling period in its history --- Q3 of 2000. * FDA approval for EBA and Lung Scanning significantly increased marginal economic value of scanner, and greatly expanded prospective target markets. * FDA approval for EB-Endoscopy is expected any week now, sometime during Q3. This will include revolutionary virtual colon scanning, and bronchia scanning. Imatron is covering all the bases. * Enormous accumulation of overwhelmingly positive peer research on EBCT. * 4 months to get sales 'out the door' --- bulge of new orders now starting to ship. * Imatron marketing division is now really rolling, under great leadership of Terry Ross, Imatron President (IMAT's biggest single owner, with over 7,000,000 shares). * Newly established 'Percentile Calcium Scoring' is huge plus, just starting to flower. * Public awareness increasing exponentially from advertising by growing base of installed scanner sites, and by news stories covering this new and exciting technology. * Public now asking their doctors about their possibly needing these scans. * Insurance companies now paying when doctors 'direct' their patients to get scanned. * Electron Beam Angiography is NON-INVASIVE. Hospitals can release patients 2-3 days sooner when they've had EBAs instead of invasive, painful, potentially life threatening, expensive angiograms. Cost savings are substantial. Knowledgeable patients will demand the non-invasive route. * New Imatron Board member, Dr. Richard K. Myler, is the co-developer of coronary angioplasty. Major figure in the industry. I've met him, and he has gone through fascinating transformation in his feelings about EBCT, from skeptic, to now very staunch supporter. If he sees the light, others will also. * EBCT is proprietary technology and solely patented by Imatron. As for the patent eventually running out, Imatron Investor Relations Robin Kelley said that since the original patent was received Imatron has built, and strongly continues R&D, "layer upon layer" onto it, making the patents rock solid. * Imatron is now prototyping a SCAN VAN --- EBCT on wheels. The applications to buy one of these has been amazing. Imatron is quite excited that these Scan Vans will put EBCT technology **all throughout the US, not just the major cities. * CEO Lewis Meyer confidently suggested in his recent Investor Conference Call, when directly asked about a BUY-OUT, that Imatron would very likely be bought out "as soon as we put some [scanner sales] numbers on the 'board'". Meyer is heading Imatron for the buy-out! * New Imatron Board member, M. Allen Chozen, specializes in mergers and acquisitions, especially selling a small growing company (Imatron) to a larger established company (GE, Siemens, Toshiba, etc.). * For the first time ever, Imatron started being watched by notable stock analysts. Respected stock picker Gene Inger put IMAT on his buy list with a target of $6 to $7. He pointed out that IMAT is the only 'small' stock on his list. Out of thousands of candidate small stocks, why did Inger choose IMAT at this time??? * Third straight quarter of positive earnings. Third straight quarter of rising profits. And this trend will continue, and accelerate. * "IMAT 2000 sure ain't your Daddy's Oldsmobile." This gem is a rocket-ship, with engines rumbling. *** Price target: Above $10, in magnificent multi-week buying flurry. Stay tuned!!